HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells

HDAC6 is overexpressed in ovarian cancer and is known to be correlated with tumorigenesis. Accordingly, ACY-241, a selective HDAC6 inhibitor, is currently under clinical trial and has been tested in combination with various drugs. HDAC8, another member of the HDAC family, has recently gained attenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji Yoon, Han, Seung Yoon, Yoo, Jung, Kim, Go Woon, Jeon, Yu Hyun, Lee, Sang Wu, Park, Jongsun, Kwon, So Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369251/
https://www.ncbi.nlm.nih.gov/pubmed/35955780
http://dx.doi.org/10.3390/ijms23158645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369251/
https://www.ncbi.nlm.nih.gov/pubmed/35955780
http://dx.doi.org/10.3390/ijms23158645

Ejemplares similares